<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Qureator - Precision Architecture</title>
  <!-- Link to external CSS -->
  <link rel="stylesheet" href="style.css" />
  <!-- Include a Google Font (optional) -->
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link
    href="https://fonts.googleapis.com/css2?family=Roboto:wght@300;400;500;700&display=swap"
    rel="stylesheet"
  />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
</head>
<body>
  <!-- HEADER / NAVBAR -->
  <header class="main-header">
    <div class="container">
      <div class="logo">
        <!-- Replace text logo with an <img> if you have a logo image -->
        <h1>Valfard Therapeutics</h1>
      </div>
      <!-- <nav class="main-nav">
        <ul>
          <li><a href="#">Home</a></li>
          <li><a href="#">Applications</a></li>
          <li><a href="#">Technology</a></li>
          <li><a href="#">About</a></li>
          <li><a href="#">Contact</a></li>
        </ul>
      </nav> -->
    </div>
  </header>

  <!-- HERO SECTION -->
  <section class="hero-section">
    <div class="hero-overlay"></div>
    <div class="container hero-content">
      <h2>Pioneering innovative biomaterial-based growth factor delivery for treating Stage I & II diabetic foot ulcers</h2>
    </div>
  </section>

  <!-- WHO WE ARE -->
  <section class="who-we-are-section">
    <div class="container who-we-are-content">
      <div class="text-content">

        <h2>About Us</h2>
        <div class="image-content">
            <div class="circle-image">
              <!-- Replace with your actual image -->
              <img src="aboutImage.jpg" alt="Microscopy Image 1" />
            </div>
          </div>
        <p>
            At Valfard Therapeutics, we are redefining the treatment of diabetic foot ulcers (DFUs) by addressing the root cause rather than just managing symptoms. Our enzyme-responsive biomaterial technology delivers controlled, sustained release of TGF-β, promoting faster healing, reducing amputations, and setting a new standard in DFU care.        </p>
      </div>
    </div>
  </section>




  <!-- FOOTER -->
  <footer class="main-footer">
    <div class="container footer-content">
      <div class="footer-left">
        <h2>Valfard Therapeutics</h2>

    <div class="footer-bottom">
      <p>© 2025 Valfard Therapeutics , Inc. All Rights Reserved.</p>
      <p>Technology and images by Valfard Therapeutics</p>
    </div>
  </footer>
</body>
</html>
